These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 2179931)

  • 1. Recent neurochemical and pharmacological aspects of pathogenesis and therapy of affective psychoses.
    Emrich HM; Wolf R
    Pharmacol Toxicol; 1990; 66 Suppl 3():5-12. PubMed ID: 2179931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance spectroscopy: neurochemistry and treatment effects in affective disorders.
    Moore GJ; Galloway MP
    Psychopharmacol Bull; 2002; 36(2):5-23. PubMed ID: 12397837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The structure of psychopharmacological revolutions.
    Healy D
    Psychiatr Dev; 1987; 5(4):349-76. PubMed ID: 3328200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The action of mood-stabilizers in affective disorders: an integrative view as a challenge.
    Emrich HM; Dose M; Wolf R
    Neuropsychobiology; 1993; 27(3):158-62. PubMed ID: 8232832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mood disorders: treatment-induced changes in brain neurochemistry and structure.
    Glitz DA; Manji HK; Moore GJ
    Semin Clin Neuropsychiatry; 2002 Oct; 7(4):269-80. PubMed ID: 12382209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance spectroscopy in affective disorders.
    Kato T; Inubushi T; Kato N
    J Neuropsychiatry Clin Neurosci; 1998; 10(2):133-47. PubMed ID: 9608402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurochemical correlates of affective disorders and their treatment. A satellite symposium affiliated to the XVIth C.I.N.P. Congress. August 21-24, 1988.
    Pharmacol Toxicol; 1990; 66 Suppl 3():1-159. PubMed ID: 2315271
    [No Abstract]   [Full Text] [Related]  

  • 8. [Glutamatergic conception of mood disorders].
    Permoda-Osip A; Rybakowski J
    Psychiatr Pol; 2011; 45(6):875-88. PubMed ID: 22335130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurochemical mechanisms in the affective disorders and neuroendocrine correlates.
    Risch SC; Kalin NH; Murphy DL
    J Clin Psychopharmacol; 1981 Jul; 1(4):180-5. PubMed ID: 6117585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical role of brain-derived neurotrophic factor in mood disorders.
    Hashimoto K; Shimizu E; Iyo M
    Brain Res Brain Res Rev; 2004 May; 45(2):104-14. PubMed ID: 15145621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological challenge strategies: implications for neurochemical mechanisms in affective disorders and treatment approaches.
    Risch SC; Kalin NH; Murphy DL
    J Clin Psychopharmacol; 1981 Jul; 1(4):238-43. PubMed ID: 6117587
    [No Abstract]   [Full Text] [Related]  

  • 12. 5-Hydroxytryptamine in the pathogenesis of affective disorders.
    Coppen A; Wood K
    Adv Biochem Psychopharmacol; 1982; 34():249-58. PubMed ID: 6753513
    [No Abstract]   [Full Text] [Related]  

  • 13. Toward an integrative model of the spectrum of mood, behavioral and personality disorders based on fear and anger traits: II. Implications for neurobiology, genetics and psychopharmacological treatment.
    Lara DR; Akiskal HS
    J Affect Disord; 2006 Aug; 94(1-3):89-103. PubMed ID: 16712943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures.
    Post RM; Weiss SR
    Mol Neurobiol; 1996 Aug; 13(1):33-60. PubMed ID: 8892335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rhythm and mood: relationships between the circadian clock and mood-related behavior.
    Schnell A; Albrecht U; Sandrelli F
    Behav Neurosci; 2014 Jun; 128(3):326-43. PubMed ID: 24660658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated administration of antidepressant drugs reduces regional somatostatin concentrations in rat brain.
    Kakigi T; Maeda K; Kaneda H; Chihara K
    J Affect Disord; 1992 Aug; 25(4):215-20. PubMed ID: 1358930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia.
    Hudson CJ; Young LT; Li PP; Warsh JJ
    Synapse; 1993 Mar; 13(3):278-93. PubMed ID: 8497811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent trends on the role of epigenomics, metabolomics and noncoding RNAs in rationalizing mood stabilizing treatment.
    Pisanu C; Katsila T; Patrinos GP; Squassina A
    Pharmacogenomics; 2018 Jan; 19(2):129-143. PubMed ID: 29199496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications.
    Manji HK; Bebchuk JM; Moore GJ; Glitz D; Hasanat KA; Chen G
    J Clin Psychiatry; 1999; 60 Suppl 2():27-39; discussion 40-1, 113-6. PubMed ID: 10073385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The obsessive-compulsive disorder. Pharmacotherapeutic and neurobiological aspects and the relation to affective pathology].
    Fornaro P
    Minerva Psichiatr; 1988; 29(2):95-103. PubMed ID: 3057306
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.